Biohaven enrolls patients in Phase 3 Graves' disease trial
Tweet Send to a Friend
Biohaven Ltd. (NYSE: BHVN) announced that its Phase 3 trial of BHV-1300 in Graves' disease is actively enrolling patients at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE




